5 Key Takeaways

• 1

  Diabetic retinopathy (DR) affects nearly one-third of individuals with diabetes and is a leading cause of preventable vision loss globally.

• 2

  Recent advancements in therapy and technology are improving the management and treatment durability of diabetic retinopathy.

• 3

  Faricimab, a bispecific antibody, targets both VEGF-A and Ang-2, addressing vascular destabilization in diabetic retinopathy.

• 4

  Biosimilars for ranibizumab and aflibercept are expanding, offering cost-effective alternatives for long-term diabetic retinopathy treatment.

• 5

  Gene therapy, such as surabgene lomparvovec, shows promise in reducing treatment burden by enabling continuous intraocular production of anti-VEGF agents.